



VACCINE-INDUCED THROMBOTIC THROMBOCYTOPAENIA

RMA ID Number	Reference List for RMA457-1 as at February 2022
------------------	---

103674	Al-Maqbali JS, Al Rasbi S, Kashoub MS, et al (2021). A 59-year-old woman with extensive deep vein thrombosis and pulmonary thromboembolism 7 days following a first dose of the pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. <i>Am J Case Rep</i> , 22: e932946.
103675	Alonso-Beato R, Morales-Ortega A, Fernandez FJ, et al (2021). Immune thrombocytopenia and COVID-19: Case report and review of literature. <i>Lupus</i> , 30(9): 1515-21.
104338	Australian Technical Advisory Group (2021). Australian Technical Advisory Group on Immunisation (ATAGI) weekly COVID-19 meeting on 11 August 2021 update. Retrieved 19 January 2022, from https://www.health.gov.au/news/australian-technical-advisory-group-on-immunisation-atagi-weekly-covid-19-meeting-on-11-august-2021-update
103678	Banerjee S, Sandhu M, Tonzi E, et al (2021). Immune-mediated thrombocytopenia associated with Ad26.COV2.S (Janssen; Johnson & Johnson) vaccine. <i>Am J Ther</i> , 28(5): e604-6.
103677	Barda N, Dagan N, Ben-Shlomo Y, et al (2021). Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. <i>N Engl J Med</i> , 385(12): 1078-90.
103679	Bhattacharjee S, Banerjee M (2020). Immune thrombocytopenia secondary to COVID-19: a systematic review. <i>SN Compr Clin Med</i> , Online ahead of print.
104346	Brighton Collaboration (2021). Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with thrombocytopenia Syndrome (TTS). Retrieved 19 January 2022, from https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-Case-Definition-v10.16.3-May-23-2021.pdf
100277	Cari L, Fiore P, Naghavi Alhosseini M, et al (2021). Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. <i>J Autoimmun</i> , Online ahead of print.
103680	Carli G, Nichele I, Ruggeri M, et al (2021). Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. <i>Intern Emerg Med</i> , 16(3): 803-4.
99052	Centers for Disease Control (2021). Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination. Retrieved 4 June 2021, from https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf

78061	Chang ET, Adami HO, Boffetta P, et al (2014). A critical review of perfluorooctanoate and perfluorooctanesulfonate exposure and cancer risk in humans. <i>Crit Rev Toxicol</i> , 44(Suppl 1): 1-81.
104343	Chen R, Buttery J (2021). Updated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS). Retrieved 15 November 2021, from TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdf
99053	Chen RT (2021). Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). Retrieved 4 June 2021, from https://brightoncollaboration.us/wp-content/uploads/2021/04/TTS-Case-Finding-and-Definition-Process.v1.0-1-1.pdf
103681	Chen VM, Curnow JL, Tran HA, et al (2021). Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. <i>Med J Aust</i> , 215(6): 245-249.e1.
103682	Daian E Silva DS, da Fonseca FG (2021). The rise of vectored vaccines: A legacy of the COVID-19 global crisis. <i>Vaccines (Basel)</i> , 9(10): 1101.
98857	Department of Health (2021). Thrombosis with thrombocytopenia syndrome (TTS). Retrieved 2 June 2021, from https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/learn-about-covid-19-vaccines/about-the-astrazeneca-covid-19-vaccine#thrombosis-with-thrombocytopenia-syndrome-tts
99056	Department of Health (2021). Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca. Retrieved 4 June 2021, from https://www.health.gov.au/news/joint-statement-from-atagi-and-thanz-on-thrombosis-with-thrombocytopenia-syndrome-tts-and-the-use-of-covid-19-vaccine-astrazeneca
103683	Dias L, Soares-Dos-Reis R, Meira J, et al (2021). Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. <i>J Stroke Cerebrovasc Dis</i> , 30(8): 105906.
103684	Favaloro EJ, Pasalic L, Lippi G (2021). Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). <i>Clin Chem Lab Med</i> , 60(1): 7-17.
98855	Franchini M, Liumbruno GM, Pezzo M (2021). COVID-19 Vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. <i>Eur J Haematol</i> , Online ahead of print.
103703	Garcia-Malo C, Peralta SR, Garcia-Borreguero D (2020). Restless legs syndrome and other common sleep-related movement disorders. <i>Continuum (Minneap Minn)</i> , 26(4): 963-87.
103685	Gordon SF, Clothier HJ, Morgan H, et al (2021). Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. <i>Vaccine</i> , 39(48): 7052-7.
103686	Hafeez MU, Ikram M, Shafiq Z, et al (2021). COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): A systematic review and post hoc analysis. <i>Clin Appl Thromb Hemost</i> , 27: 10760296211048815.
103687	Hippisley-Cox J, Patone M, Mei XW, et al (2021). Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. <i>BMJ</i> , 374: n1931.
103688	Hocking J, Chunilal SD, Chen VM, et al (2021). The first known case of vaccine-induced thrombotic thrombocytopenia in Australia. <i>Med J Aust</i> , 215(1): 19-20.e1.

103689	Huh K, Na Y, Kim YE, et al (2021). Predicted and observed incidence of thromboembolic events among Koreans vaccinated with ChAdOx1 nCoV-19 vaccine. <i>J Korean Med Sci</i> , 36(27): e197.
103690	Kim G, Choi EJ, Park HS, et al (2021). A case report of immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. <i>J Korean Med Sci</i> , 36(43): e306.
103691	Klein NP, Lewis N, Goddard K, et al (2021). Surveillance for adverse events after COVID-19 mRNA vaccination. <i>JAMA</i> , 326(14): 1390-9.
103692	Krzywicka K, Heldner MR, Sanchez van Kammen M, et al (2021). Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. <i>Eur J Neurol</i> , 28(11): 3656-62.
103693	Kuter DJ (2021). Exacerbation of immune thrombocytopenia following COVID-19 vaccination. <i>Br J Haematol</i> , 195(3): 365-70.
103695	Lee EJ, Beltrami Moreira M, Al-Samkari H, et al (2021). SARS-CoV-2 vaccination and immune thrombocytopenia in de novo and pre-existing ITP patients. <i>Blood</i> , Online ahead of print.
103694	Lee GM, Arepally GM (2013). Heparin-induced thrombocytopenia. <i>Hematology Am Soc Hematol Educ Program</i> , 2013: 668-74.
78060	Lei M, Zhang L, Lei J, et al (2015). Overview of emerging contaminants and associated human health effects. <i>Biomed Res Int</i> , 2015: 404796.
103696	Levin D, Shimon G, Fadlon-Derai M, et al (2021). Myocarditis following COVID-19 vaccination - A case series. <i>Vaccine</i> , 39(42): 6195-200.
103697	Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. <i>Lancet</i> , 397(10275): 671-681.
103698	Lundstrom K, Barh D, Uhal BD, et al (2021). COVID-19 vaccines and thrombosis-roadblock or dead-end street? <i>Biomolecules</i> , 11(7): 1020.
103699	Malik B, Kalantary A, Rikabi K, et al (2021). Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. <i>BMJ Case Rep</i> , 14(7): e243975.
103700	Mingot-Castellano ME, Alcalde-Mellado P, Pascual-Izquierdo C, et al (2021). Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain. <i>Br J Haematol</i> , 194(3): 537-41.
103701	Muir KL, Kallam A, Koepsell SA, et al (2021). Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. <i>N Engl J Med</i> , 384(20): 1964-5.
101438	Nazi I, Arnold DM, Warkentin TE, et al (2015). Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia. <i>J Thromb Haemost</i> , 13(10): 1900-7.
103702	Ogai A, Yoshida R, Yuasa C, et al (2021). Acute immune thrombocytopenia following SARS-CoV-2 vaccination in chronic ITP patients and a healthy individual. <i>Int J Hematol</i> , Online ahead of print.
103709	Pavord S, Scully M, Hunt BJ, et al (2021). Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. <i>N Engl J Med</i> , 385(18): 1680-9.
103710	Perry RJ, Tamborska A, Singh B, et al (2021). Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. <i>Lancet</i> , 398(10306): 1147-56.
103711	Pishko AM, Cuker A (2021). Thrombosis after vaccination with messenger RNA-1273: Is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia Syndrome? <i>Ann Intern Med</i> , 174(10): 1468-9.

99057	Pottegard A, Lund LC, Karlstad O, (2021). Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. <i>BMJ</i> , 373: n1114.
103712	Prince M, Wenham T (2018). Heparin-induced thrombocytopenia. <i>Postgrad Med J</i> , 94(1114): 453-7.
99054	Queensland Health (2021). Information for clinicians - thrombosis with thrombocytopenia syndrome (TTS) or vaccine induced prothrombotic immune thrombocytopenia (VIPIT). Retrieved 4 June 2021, from https://www.health.qld.gov.au/_data/assets/pdf_file/0024/1036671/covid-19-vaccination-tts-vipit.pdf
103713	Rizk JG, Gupta A, Sardar P, et al (2021). Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. <i>JAMA Cardiol</i> , Online ahead of print.
103714	Rodriguez EC, Bouazza FZ, Dauby N, et al (2021). Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COVS.2.S: first documented case outside US. <i>Infection</i> , Online ahead of print.
103715	Sadoff J, Davis K, Douoguih M (2021). [Comment] Thrombotic thrombocytopenia after Ad26.COVS.2.S vaccination - response from the manufacturer. <i>N Engl J Med</i> , 384(20): 1965-6. Comment on ID: 103701.
103721	Sanchez van Kammen M, Heldner MR, Brodard J, et al (2021). Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. <i>JAMA</i> , 326(4): 332-8.
103716	Sangli S, Virani A, Cheronis N, et al (2021). Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. <i>Ann Intern Med</i> , 174(10): 1480-2.
103717	Schonborn L, Thiele T, Kaderali L, et al (2021). Decline in pathogenic antibodies over time in VITT. <i>N Engl J Med</i> , 385(19): 1815-6.
98856	See I, Su JR, Lale A, et al (2021). US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COVS.2.S vaccination, March 2 to April 21, 2021. <i>JAMA</i> , Online ahead of print.
104341	Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, et al (2021). Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. <i>J Neurol Sci</i> , 428: 117607.
100276	Simpson CR, Shi T, Vasileiou E, et al (2021). First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. <i>Nat Med</i> , Online ahead of print.
103718	Syed K, Chaudhary H, Donato A (2021). Central venous sinus thrombosis with subarachnoid hemorrhage following an mRNA COVID-19 vaccination: Are these reports merely co-incidental? <i>Am J Case Rep</i> , 22: e933397.
103719	Taquet M, Husain M, Geddes JR, et al (2021). Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases. <i>EClinicalMedicine</i> , 39: 101061.
99055	THANZ (2021). Suspected vaccine induced immune thrombotic thrombocytopenia (VITT) THANZ advisory statement for haematologists. Retrieved 4 June 2021, from https://www.thanz.org.au/documents/item/591
60822	The Uppsala Monitoring Centre (2011). The use of the WHO-UMC system for standardised case causality assessment. Retrieved 30 May 2011, from http://who-umc.org/Graphics/24734.pdf
104332	Therapeutic Goods Administration (2021). COVID-19 vaccine weekly safety report - 12-08-2021. Retrieved 19 January 2022, from https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-12-08-2021

104334	Therapeutic Goods Administration (2021). COVID-19 vaccine weekly safety report - 16-09-2021. Retrieved 19 January 2022, from https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-16-09-2021
104335	Therapeutic Goods Administration (2021). COVID-19 vaccine weekly safety report - 28-10-2021. Retrieved 19 January 2022, from https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-28-10-2021
104336	Therapeutic Goods Administration (2021). COVID-19 vaccine weekly safety report - 11-11-2021. Retrieved 19 January 2022, from https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-11-11-2021
99058	Therapeutic Goods Administration (2021). COVID-19 vaccine weekly safety report - 27-05-21. Retrieved 4 June 2021, from https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-27-05-2021
100704	Therapeutics Goods Administration (2021). COVID-19 vaccine weekly safety report - 08-07-2021. Retrieved 19 July 2021, from https://www.tga.gov.au/periodic/covid-19-vaccine-weekly-safety-report-08-07-2021
103720	Uzun G, Althaus K, Bakchoul T (2021). No correlation between anti-PF4 and anti-SARS-CoV-2 antibodies after ChAdOx1 nCoV-19 vaccination. <i>N Engl J Med</i> , 385(14): 1334-6.
103722	Welsh KJ, Baumblatt J, Chege W, et al (2021). Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). <i>Vaccine</i> , 39(25): 3329-32.
104340	World Health Organization (2021). Guidance for clinical case management of thrombosis with thrombocytopenia syndrome(TTS) following vaccination to prevent coronavirus disease (COVID-19). Retrieved 19 January 2022, from https://www.who.int/publications/i/item/WHO-2019-nCoV-TTS-2021.1
103723	Wu S, Huang J, Zhang Z, et al (2021). Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. <i>Lancet Infect Dis</i> , 21(12): 1654-64.
103724	Zakaria Z, Sapiai NA, Ghani AR (2021). Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine. <i>Acta Neurochir (Wien)</i> , 163(8): 2359-62.